Fast database lock in a complex Phase III diabetes study

Phase III diabetes studies with adaptive dosing and multiple treatment arms require robust Randomization and Trial Supply Management (RTSM) execution, real-time data capture, and strict drug supply control to meet aggressive timelines.

This study combined complex RTSM logic and site-specific laboratory variability under aggressive delivery timelines, achieving database go-live ahead of the planned timeline and database lock within 3 days after Last Patient Last Visit (LPLV), supported by stable real-time data entry (>99%) and uninterrupted trial conduct.

Challenge

From the outset, the study presented several high-risk operational and technical challenges:

• Multiple treatment arms with visit-driven dose titration based on hemoglobin (HbA1c) values
• Advanced RTSM logic to support arm-specific kit allocation and continuous drug availability
• Frequent priority changes requiring fast system updates and validation
• Tight delivery timelines driven by aggressive study milestones
• Site-specific laboratory reference ranges and units requiring standardized configuration within the system
• A critical mid-study amendment to lab reference ranges requiring controlled implementation without affecting historical sample integrity

Solution

To manage these demands, the study was built on oomnia’s integrated Electronic Data Capture (EDC), RTSM, and Local Lab environment to support complex study execution requirements.

Integrated EDC–RTSM execution

• Mirrored CRFs across EDC and RTSM to maintain consistency and reduce reconciliation efforts
• Tight integration between EDC and RTSM for real-time data exchange
• Adaptive, rule-based RTSM design aligned with protocol-driven dose titration

Adaptive RTSM configuration

The RTSM setup was engineered to support complex operational needs and advanced architectural features:

• Rule-based dose escalation aligned with protocol requirements
• Generalized and arm-specific kit setup
• End-to-end drug supply oversight, including dispensing and site-to-site transfers

Urgent RTSM requests were addressed through rapid configuration updates, close operational coordination, and expedited validation cycles.

Local lab data standardization

The Local Lab Module played a significant role in improving data quality and reducing data entry errors.

• Local laboratories were mapped per site within the system
• Reference ranges and units were automatically populated in CRFs based on test, age group, gender, and laboratory
• Manual interpretation was eliminated, significantly reducing discrepancies and queries

A mid‑study lab reference range amendment was executed safely through detailed impact analysis and a clearly defined cut-off based on sample collection dates, preserving data integrity across the study.

Proactive technical support

Two isolated RTSM numbering inconsistencies were identified during execution. One duplicate screening/randomization number and one skipped number.

Results

The integrated approach delivered measurable operational and data‑quality gains:

• Database go-live achieved ahead of schedule
• Database lock completed within 3 days after LPLV
• Over 99% real-time data entry maintained at any point in time
• Zero RTSM dispensing errors
• Reduced reconciliation efforts through mirrored CRFs across EDC and RTSM
• Real-time data review enabled through ad-hoc reporting and exports, significantly reducing operational turnaround time

About the trial

The project focused on executing a complex Phase III diabetes study requiring controlled randomization, adaptive dose titration, and uninterrupted investigational product supply across 18 sites in India with 236 enrolled patients.

The study relied on an integrated EDC and RTSM environment compliant with the International Council for Harmonization—Good Clinical Practice (ICH‑GCP) and the Drug Controller General of India (DCGI), capable of handling adaptive logic, site‑specific laboratory configurations, and rapid mid‑study updates without compromising data integrity.

oomnia supported consistent data capture, protocol-driven RTSM execution, and timely study close-out.

Project outcome

The study achieved database lock within 3 days after LPLV, enabling the sponsor to save time for post-lock activities and regulatory submission. This outcome was supported by adaptive RTSM configuration, standardized local lab setup, priority-based RTSM support, and active involvement of the clinical operations teams.

Overall, prioritized RTSM support, flexible system configuration, and coordinated execution contributed to achieving the study milestones within aggressive timelines.

About Velocious Clinical Research

Velocious Clinical Research supports pharmaceutical companies, CROs, medical device, nutraceutical, and Ayurveda organizations in managing one of their most critical assets—clinical trial data.

Combining regulatory-compliant processes, specialized expertise, cost efficiency, and uncompromised quality, Velocious delivers inspection-ready, statistically sound data within agreed timelines to support confident clinical decision-making.

The team specializes in the design, collection, analysis, and structuring of global, multi-centric trial data for regulatory submission, supported by robust SOPs and audit-ready clinical database systems. Continuous improvement and client feedback remain central to ensuring consistent quality and operational excellence.

For more information visit: https://www.velociouscr.com/

About Wemedoo

Wemedoo is the creator of oomnia, a unified clinical research information system that integrates EDC, electronic Clinical Outcome Assessment (eCOA), electronic Patient-Reported Outcomes (ePRO), Clinical Trial Management System (CTMS), electronic Informed Consent (eConsent) , electronic Source Data (eSource), RTSM, and electronic Trial Master File (eTMF).

oomnia enables sponsors to run complex decentralized and hybrid trials faster and more securely with a better patient experience, all in full compliance with global regulatory standards.